Abbott Laboratories(ABT)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Latest News & Analysis
Abbott (ABT): Volt PFA Approval, TriClip Success, and Market Outlook
Abbott Laboratories (ABT) navigates market volatility with Volt PFA approval, TriClip success, and a consistent dividend history, making it a stable investment.
Abbott (ABT): PFA Approval, Coronary IVL System, and Market Outlook
Abbott Laboratories (ABT) gains momentum with CE Mark approval for Volt™ PFA and FDA IDE nod for Coronary IVL, bolstering its cardiovascular portfolio.
Abbott (ABT): FDA Approval, Market Impact, and Future Growth
Analysis of Abbott Laboratories (ABT): FDA approval for Coronary IVL System, AI initiatives, dividend growth, and strategic focus on diabetes care and weight-loss.
Abbott Laboratories: Coronary IVL, Weight Loss, and AI Driving Growth
Abbott Laboratories is strategically positioned for growth through medical devices, expansion into weight-loss, and AI integration. Dividend payouts and financial stability enhance its appeal.
Abbott (ABT): Growth, Dividends, and Market Outlook 2025
Abbott Laboratories (ABT) navigates market dynamics with strategic expansions, FreeStyle Libre advancements, and dividend reliability. A detailed analysis for investors.
Abbott Laboratories (ABT): Earnings, Dividends, and Growth Analysis
A deep dive into Abbott Laboratories' recent performance, dividend aristocrat status, and growth prospects. Discover how strategic initiatives and market dynamics shape ABT's future.
Abbott Laboratories: Intraday Market Update - March 5, 2025
Intraday update on Abbott Laboratories (ABT) with key financial metrics, dividend news, strategic moves, and market trends from credible sources.
Abbott Laboratories: Analyzing Growth Drivers and Future Outlook
Abbott Laboratories (ABT) navigates 2025 with strong performance, driven by FreeStyle Libre and molecular diagnostics, despite FX headwinds. Dividend Aristocrat status enhances investor appeal.
Abbott (ABT) in 2025: Dividend King, Diabetes Care Leader
Abbott Laboratories (ABT) shows strong 2025 performance driven by dividends, diabetes care, and diagnostics growth, despite FX risks. A detailed analysis follows.
Abbott Laboratories (ABT): Growth, Dividends, and Market Leadership
Comprehensive analysis of Abbott Laboratories (ABT): exploring diabetes care innovations, molecular diagnostics growth, dividend consistency, and future outlook.
Abbott Laboratories (ABT): Navigating Growth in Diabetes Care & Diagnostics
**Abbott Laboratories (ABT) demonstrates resilience and growth potential.** Driven by FreeStyle Libre and expansion in molecular diagnostics, the company maintains a steady climb.
Abbott Laboratories: Growth Drivers, Market Trends, and Future Outlook
Abbott Laboratories navigates a dynamic healthcare landscape with consistent dividends, FreeStyle Libre growth, and molecular diagnostics opportunities. A comprehensive analysis of ABT's market position.
Abbott Laboratories: Dividends, Diabetes Care & Market Trends
Abbott continues to deliver consistent dividends, robust diabetes care growth, and expanding diagnostics in a competitive healthcare landscape.
Abbott Laboratories: Navigating Growth in Diabetes Care
Abbott Laboratories demonstrates resilience amid market volatility, driven by growth in diabetes care and strategic market expansion. ABT stock increases +0.79%.
Abbott Laboratories: Navigating Growth in Diagnostics, Diabetes Care, and Dividends
A comprehensive data-driven analysis of Abbott’s Q4 performance, R&D investments, and market trends shaping its future.